Ethyl (HE), propyl (HP), butyl (HB), octyl (HO) and decyl (HD) O-acyl esters of haloperidol (HA) were evaluated for permeation across full-thickness human and guinea pig skin. The inclusion of 0.5mgmL−1 cetrimide as a receptor phase solubilising agent did not significantly alter the barrier properties of the membranes. The permeation of the parent drug, HA, across guinea pig skin was found to be greater than that of its derivatives. Prodrug hydrolysis by cutaneous esterases was minimal. The permeation of HE, HP and HB across freshly excised guinea pig skin was subsequently investigated, however, prodrug hydrolysis remained low. Hydrolysis studies using a skin extract revealed only limited prodrug metabolism. However, in the presence of a liver extract, hydrolysis of all prodrugs was rapid. It was proposed that GGGX esterases, required for the hydrolysis of tertiary esters, were not present at a sufficiently high concentration within the skin for substantial prodrug hydrolysis to occur. This does not necessarily detract from the system as post-transdermal delivery liberation of HA in vivo is an equally useful mode for delivering this drug to the systemic circulation.

The aim of this work was to produce a thin, flexible and diffusion able molecularly imprinted polymeric matrix with good template accessibility. Membranes were prepared using a non-covalent molecular imprinting approach and their physical characteristics and binding capabilities investigated. Two materials were used, a poly(tri-ethyleneglycol dimethyacrylate-co-methyl methacrylate-co-methacrylic acid) copolymer containing 14% cross-linker and a monomer (g) to porogen (ml) ratio of 1:0.5 (A), and a blend of poly(TEGMA-co-MAA) and polyurethane (B). The polyurethane was added to improve membrane flexiblity and stability. The polymers were characterized using AFM, SEM and nitrogen adsorption, whilst binding was evaluated using batch-rebinding studies. For all membranes the specific surface area was low (<10 m(2)/g). MIP (A) films were shown to bind specifically at low concentrations but specific binding was masked by non-specific interactions at elevated concentrations. Selectivity studies confirmed specificity at low concentrations. K(D) approximations confirmed a difference in the population of binding sites within NIP and MIP films. The data also indicated that at low concentrations the ligand-occupied binding site population approached homogeneity. Scanning electron microscopy images of membrane (B) revealed a complex multi-layered system, however these membranes did not demonstrate specificity for the template. The results described here demonstrate how the fundamental parameters of a non-covalent molecularly imprinted system can be successfully modified in order to generate flexible and physically tolerant molecularly imprinted thin films.

In probing enhancement of the transdermal delivery of the anti-psychotic drug haloperidol, five prodrugs (ethanoate, propanoate, butanoate, octanoate and decanoate) were synthesised and their relative rates of hydrolysis determined in the presence of porcine liver esterase (PLE), a model for cutaneous esterases. (1)H NMR, MS and elemental analysis confirmed the successful synthesis of each prodrug in high purity, and each was found to hydrolyse in the presence of PLE with the hydrolytic rate reaching a maximum with haloperidol octanoate (C8) at 2.31 +/- 0.06 nmol ml(-1) h(-1) (p < 0.001).

Microneedles disrupt the stratum corneum barrier layer of skin creating transient pathways for the enhanced permeation of therapeutics into viable skin regions without stimulating pain receptors or causing vascular damage. The cutaneous delivery of nucleic acids has a number of therapeutic applications; most notably genetic vaccination. Unfortunately non-viral gene expression in skin is generally inefficient and transient. This study investigated the potential for improved delivery of plasmid DNA (pDNA) in skin by combining the microneedle delivery system with sustained release pDNA hydrogel formulations.

INTRODUCTION The skin represents an attractive site for the delivery of nucleic-acid-based drugs for the treatment of topical or systemic diseases and immunization. However, attempts at therapeutic cutaneous gene delivery have been hindered by several factors. Usually, except for viral vectors, gene expression is transient and typically disappears with one to two weeks due to the continuous renewal of the epidermis. Moreover, DNA penetration is limited by the barrier properties of the skin, rendering topical application rather inefficient.

The stratum corneum (SC) represents a significant barrier to the delivery of gene therapy formulations. In order to realise the potential of therapeutic cutaneous gene transfer, delivery strategies are required to overcome this exclusion effect. This study investigates the ability of microfabricated silicon microneedle arrays to create micron-sized channels through the SC of ex vivo human skin and the resulting ability of the conduits to facilitate localised delivery of charged macromolecules and plasmid DNA (pDNA). Microscopic studies of microneedle-treated human epidermal membrane revealed the presence of microconduits (10-20 microm diameter). The delivery of a macromolecule, beta-galactosidase, and of a 'non-viral gene vector mimicking' charged fluorescent nanoparticle to the viable epidermis of microneedle-treated tissue was demonstrated using light and fluorescent microscopy. Track etched permeation profiles, generated using 'Franz-type' diffusion cell methodology and a model synthetic membrane showed that >50% of a colloidal particle suspension permeated through membrane pores in approximately 2 hours. On the basis of these results, it is probable that microneedle treatment of the skin surface would facilitate the cutaneous delivery of lipid:polycation:pDNA (LPD) gene vectors, and other related vectors, to the viable epidermis. Preliminary gene expression studies confirmed that naked pDNA can be expressed in excised human skin following microneedle disruption of the SC barrier. The presence of a limited number of microchannels, positive for gene expression, indicates that further studies to optimise the microneedle device morphology, its method of application and the pDNA formulation are warranted to facilitate more reproducible cutaneous gene delivery.

An atrazine (ATR) molecularly imprinted polymer (MIP) was prepared using a non-covalent strategy. The affinity and selectivity of the polymer was initially evaluated under non-equilibrium conditions and the polymer was shown to possess good template selectivity. The selectivity of the polymer was further investigated under equilibrium conditions and over a range of concentrations using Scatchard plots and Hill plots and by assessing distribution coefficients and normalised selectivity values. It was observed that both selectivity and affinity were dependent on the concentration of the ligand and that unusually selectivity and affinity were better at higher atrazine concentrations. It was concluded that this phenomenon resulted from the formation of atrazine–atrazine complexes during the pre-polymerisation stage and during rebinding and that the polymer demonstrated improved atrazine affinity when the conditions favoured complex formation.

Molecular imprinting is a generic technology that allows for the introduction of sites of specific molecular affinity into otherwise homogeneous polymeric matrices. Commonly this technique has been shown to be effective when targeting small molecules of molecular weight < 1500, while extending the technique to larger molecules such as proteins has proven difficult. A number of key inherent problems in protein imprinting have been identified, including permanent entrapment, poor mass transfer, denaturation, and heterogeneity in binding pocket affinity, which have been addressed using a variety of approaches. This review focuses on protein imprinting in its various forms, ranging from conventional bulk techniques to novel thin film and monolayer surface imprinting approaches.

The use of ATR-FTIR spectroscopy to study the permeability of a glycerogelatin film is described. Measurement of the diffusion coefficient of ethyl alcohol-d in the film showed excellent reproducibility. Comparison of results from this technique with those previously obtained using an air-flow receptor phase diffusion cell show good agreement in terms of lag time assessed diffusion coefficients. ATR-FTIR spectroscopy revealed time-dependent changes in the composition of the glycerogelatin film during the diffusional process. It was also demonstrated that the concurrent assessment of both diffusant penetration and film composition is feasible.

Previously, transdermal patches with internal pH-controlled release were described. The aim of this study was to test the suitability of the patch design in transdermal delivery and, further, to select such transdermal patch formulations to a clinical study with timolol. In vitro release of timolol from the patches was determined as well as timolol permeation across the human cadaver skin. The effect of the skin on drug release were evaluated in vitro. In vitro data and pharmacokinetic parameters from the literature were used to construct a pharmacokinetic model for the prediction of in vivo performance of the devices. With water-activated, pH-controlled silicone reservoir devices, both the rate of drug release and the duration of constant release were controlled. The rate of timolol release was decreased when the devices were placed on human cadaver skin, and thus, the skin partly controls the rate and extent of timolol delivery to the systemic circulation in vivo. On the basis of in vitro data and kinetic simulations, devices of 10-cm2 volume releasing timolol in vitro at the rates of 119 and 10 μg h−1 cm−2 were selected for human tests.

The percutaneous absorption of the polar drug methotrexate has been examined in vitro. Two alcoholic gel formulations containing 1% methotrexate with or without Azone® were applied to full-thickness abdominal human skin mounted in all-glass Franz-type diffusion cells. In the absence of Azone® no percutaneous penetration of methotrexate was observed. In the presence of Azone® 190 ng/cm2 permeated after 48 h. Azone® appears to be actingas an efficient penetration enhancer for this drug.